Dr. Reddy's Laboratories Limited
Every calculator, already run for RDY
Open the full toolkit →You have the numbers on RDY. Get the argument.
A written report on which of these readings actually decide the outcome for Dr. Reddy's Laboratories Limited, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
5 analysts covering RDYAnalyst Price Target Disagreement for Dr. Reddy's Laboratories Limited
Wall Street's bull case implies +26% from the current price; the bear case implies -7%. A 33% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for RDY
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal…
RDY — frequently asked
Is RDY a buy right now?
Wall Street's consensus rating on Dr. Reddy's Laboratories Limited is none across 5 analysts, with a mean price target of $13.36 (+9% vs. the current $12.25). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is RDY overvalued?
RDY trades at 29.9x trailing earnings. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is RDY's next earnings date?
Dr. Reddy's Laboratories Limited is next scheduled to report earnings around Oct 23, 2026. A full RDY research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Dr. Reddy's Laboratories Limited?
Analysts covering Dr. Reddy's Laboratories Limited (RDY) range from a bear-case target of $11.35 to a bull-case high of $15.38, with a mean consensus target of $13.36 across 5 analysts. The spread of $4.03 (33% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Dr. Reddy's Laboratories Limited against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Dr. Reddy's Laboratories Limited
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full RDY research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Dr. Reddy's Laboratories Limited, in minutes. 3 free reports included with every account — no credit card required.